KEMPHARM INC (KMPH) Stock Fundamental Analysis

NASDAQ:KMPH • US4884452065

5.81 USD
-0.02 (-0.34%)
Last: Feb 28, 2023, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall KMPH gets a fundamental rating of 2 out of 10. We evaluated KMPH against 192 industry peers in the Pharmaceuticals industry. The financial health of KMPH is average, but there are quite some concerns on its profitability. KMPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year KMPH has reported negative net income.
  • In the past year KMPH has reported a negative cash flow from operations.
KMPH Yearly Net Income VS EBIT VS OCF VS FCFKMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

  • KMPH has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMPH Yearly ROA, ROE, ROICKMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KMPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMPH Yearly Profit, Operating, Gross MarginsKMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • KMPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, KMPH has more shares outstanding
  • Compared to 1 year ago, KMPH has an improved debt to assets ratio.
KMPH Yearly Shares OutstandingKMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
KMPH Yearly Total Debt VS Total AssetsKMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 1.51, we must say that KMPH is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.51, KMPH is doing good in the industry, outperforming 65.16% of the companies in the same industry.
  • A Debt/Equity ratio of 0.14 indicates that KMPH is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.14, KMPH perfoms like the industry average, outperforming 42.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC8.07%
KMPH Yearly LT Debt VS Equity VS FCFKMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

  • KMPH has a Current Ratio of 10.10. This indicates that KMPH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 10.10, KMPH belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
  • A Quick Ratio of 10.10 indicates that KMPH has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 10.10, KMPH belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
KMPH Yearly Current Assets VS Current LiabilitesKMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 64.83% over the past year.
  • KMPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.30%.
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.26%

3.2 Future

  • KMPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.57% yearly.
  • Based on estimates for the next years, KMPH will show a very strong growth in Revenue. The Revenue will grow by 29.23% on average per year.
EPS Next Y-143.91%
EPS Next 2Y-23.09%
EPS Next 3Y14.78%
EPS Next 5Y37.57%
Revenue Next Year-59.96%
Revenue Next 2Y-19.37%
Revenue Next 3Y11.18%
Revenue Next 5Y29.23%

3.3 Evolution

KMPH Yearly Revenue VS EstimatesKMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
KMPH Yearly EPS VS EstimatesKMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • KMPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KMPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMPH Price Earnings VS Forward Price EarningsKMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMPH Per share dataKMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KMPH's earnings are expected to grow with 14.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.09%
EPS Next 3Y14.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

KEMPHARM INC

NASDAQ:KMPH (2/28/2023, 8:00:03 PM)

5.81

-0.02 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-09
Earnings (Next)03-28
Inst Owners83.06%
Inst Owner Change-4.18%
Ins Owners21.5%
Ins Owner Change0%
Market Cap200.47M
Revenue(TTM)10.72M
Net Income(TTM)-35.23M
Analysts84.44
Price Target22.78 (292.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.26%
Min EPS beat(2)-55.23%
Max EPS beat(2)-43.29%
EPS beat(4)1
Avg EPS beat(4)-23.05%
Min EPS beat(4)-55.23%
Max EPS beat(4)10.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.57%
Min Revenue beat(2)-29.19%
Max Revenue beat(2)-11.95%
Revenue beat(4)2
Avg Revenue beat(4)-0.26%
Min Revenue beat(4)-29.19%
Max Revenue beat(4)26.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.7
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.31
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.51
F-Score2
WACC8.07%
ROIC/WACCN/A
Cap/Depr(3y)20.27%
Cap/Depr(5y)24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
EPS Next Y-143.91%
EPS Next 2Y-23.09%
EPS Next 3Y14.78%
EPS Next 5Y37.57%
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.26%
Revenue Next Year-59.96%
Revenue Next 2Y-19.37%
Revenue Next 3Y11.18%
Revenue Next 5Y29.23%
EBIT growth 1Y-350.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-586.19%
EBIT Next 3Y-64.71%
EBIT Next 5Y46.24%
FCF growth 1Y-279.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-279.47%
OCF growth 3YN/A
OCF growth 5YN/A

KEMPHARM INC / KMPH FAQ

What is the ChartMill fundamental rating of KEMPHARM INC (KMPH) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KMPH.


Can you provide the valuation status for KEMPHARM INC?

ChartMill assigns a valuation rating of 1 / 10 to KEMPHARM INC (KMPH). This can be considered as Overvalued.


Can you provide the profitability details for KEMPHARM INC?

KEMPHARM INC (KMPH) has a profitability rating of 0 / 10.


How financially healthy is KEMPHARM INC?

The financial health rating of KEMPHARM INC (KMPH) is 6 / 10.